J. Brown

发表

FDA Approval: Belinostat for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma

Richard Pazdur, Robert Justice, Nitin Mehrotra, 2015, Clinical Cancer Research.

U.S. Food and Drug Administration Approval Summary: Brentuximab Vedotin for the Treatment of Relapsed Hodgkin Lymphoma or Relapsed Systemic Anaplastic Large-Cell Lymphoma

R. Pazdur, A. Khandelwal, F. Borrego, 2012, Clinical Cancer Research.

Subvisible Particle Content, Formulation, and Dose of an Erythropoietin Peptide Mimetic Product Are Associated With Severe Adverse Postmarketing Events.

D. Metcalfe, D. Scott, Yamei Gao, 2016, Journal of pharmaceutical sciences.

Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence.

B. Narasimhan, J. Zehnder, D. Miklos, 2012, Blood.

Diagnostic and therapeutic challenges of treating opportunistic fungal cellulitis: a case series

J. Brown, J. Paul, Mary M. Czech, 2022, BMC Infectious Diseases.

The changing impact of cytomegalovirus among hematopoietic cell transplant recipients during the past decade: A single institutional cohort study

B. Efron, B. Narasimhan, J. Brown, 2022, Transplant infectious disease : an official journal of the Transplantation Society.

Successful surgical and medical treatment of rhizopus osteomyelitis following hematopoietic cell transplantation.

N. Vashi, J. Brown, S. Arai, 2012, Orthopedics.

Letermovir Prophylaxis Decreases Burden of CMV in Patients at High Risk for CMV Disease Following Hematopoietic Cell Transplant.

B. Efron, B. Narasimhan, J. Brown, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma.

D. Miklos, B. Sahaf, C. Mackall, 2021, Blood advances.

FDA Approval: Idelalisib Monotherapy for the Treatment of Patients with Follicular Lymphoma and Small Lymphocytic Lymphoma

Lei Nie, Dhananjay D. Marathe, Richard Pazdur, 2015, Clinical Cancer Research.

U.S. Food and Drug Administration approval summary: omacetaxine mepesuccinate as treatment for chronic myeloid leukemia.

R. Pazdur, M. Rothmann, C. Ko, 2014, The oncologist.

Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: an international, multicentre, randomised, double-blind, placebo-controlled trial

G. Papanicolaou, J. Mehta, J. Panse, 2018, The Lancet.

Non-Genotoxic Anti-CD117 Antibody Conditioning Results in Successful Hematopoietic Stem Cell Engraftment in Patients with Severe Combined Immunodeficiency

I. Weissman, A. Logan, K. Weinberg, 2019, Blood.

Continuous-Infusion Foscarnet Facilitates Administration in Hematopoietic Stem Cell Transplantation Patients.

J. Brown, I. Nguyen, Joyce J. Johnsrud, 2021, Transplantation and cellular therapy.

U.S. Food and Drug Administration Approval: Carfilzomib for the Treatment of Multiple Myeloma

R. Pazdur, Jessica J. Hawes, Todd R. Palmby, 2013, Clinical Cancer Research.

JSP191 As a Single-Agent Conditioning Regimen Results in Successful Engraftment, Donor Myeloid Chimerism, and Production of Donor Derived Naïve Lymphocytes in Patients with Severe Combined Immunodeficiency (SCID)

I. Weissman, A. Logan, K. Weinberg, 2021, Blood.

283: Rituximab infusion two months after total lymphoid irradiation-antithymocyte globulin (TLI-ATG) nonmyeloablative transplantation maintains B-cell disease control with minimal GVHD

J. Zehnder, D. Miklos, B. Sahaf, 2007 .

U.S. Food and Drug Administration Approval: Carfilzomib for the Treatment of Multiple Myeloma

R. Pazdur, Jessica J. Hawes, Todd R. Palmby, 2013, Clinical Cancer Research.

Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence.

B. Narasimhan, J. Zehnder, D. Miklos, 2012, Blood.

U.S. Food and Drug Administration Approval Summary: Brentuximab Vedotin for the Treatment of Relapsed Hodgkin Lymphoma or Relapsed Systemic Anaplastic Large-Cell Lymphoma

R. Pazdur, A. Khandelwal, F. Borrego, 2012, Clinical Cancer Research.

Evaluation of Romyelocel-L Myeloid Progenitor Cells to Decrease Infections in De Novo AML Patients Receiving High-Dose Ara-C-Based Induction Therapy

S. Kambhampati, H. Kantarjian, T. Kadia, 2018, Blood.

U.S. Food and Drug Administration Approval: Carfilzomib for the Treatment of Multiple Myeloma

R. Pazdur, Jessica J. Hawes, Todd R. Palmby, 2013, Clinical Cancer Research.